

SUPPLEMENTARY MATERIAL

The diagnostic utility of miRNA21 in systemic sclerosis

Gehad Gamal Maghraby,¹ May Mohsen Tolba Fawzi,²
Laila Ahmed Rashed,³ Mohamed Tharwat Hegazy¹

¹Rheumatology and Clinical Immunology Unit, Internal Medicine Department, Faculty of Medicine, Cairo University; ²Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Cairo University; ³Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Cairo University, Egypt

Correspondence: Gehad Gamal Maghraby, Rheumatology and Clinical Immunology Unit, Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo 11241, Egypt.
E-mail: gehad.maghraby@kasralainy.edu.eg

Key words: scleroderma, systemic, microRNAs, miR-21, biomarkers, epigenetics.

Supplementary Table 1. Clinical characteristics of patients with systemic sclerosis.

Parameters of SSc patients (n=25)	N (%) or mean±SD
Sex (females), n (%)	20 (80)
Age (years)	35.36±10.24
Duration of SSc (months)	54.12±54.32
Smokers	2 (8)
Limited SSc	20 (80)
Diffuse SSc	5 (20)
Early SSc	8 (32)
Raynaud's	24 (96)
Telangiectasia	13 (52)
Digital ulcers	11 (44)
Pitting scar	16 (64)
Puffy hands	12 (48)
Dysphagia	13 (52)
Dyspnea	15 (60)
Arthralgia	22 (88)
Arthritis	6 (24)
Oral ulcers	5 (20)
Alopecia	16 (64)
Malar rash	5 (20)
Modified Rodnan Skin Score/51	10.08±11
Skin tightness beyond MCP	9 (36)
Skin tightness distal to MCP	16 (64)
Presence of interstitial lung disease	14 (56)
Presence of pulmonary hypertension	6 (28.6)
Significant peripheral vascular affection by Medsger score	17 (68)
Significant skin affection by Medsger score	6 (24)
ESR mm/hr, median (range)	25 (4-98)
C-reactive protein mg/L, median (range)	4 (2-30)
Antinuclear antibody	24 (96)
Anticentromere antibody	11 (44)
Anti-scleroderma 70	12 (48)
Patients on steroids	15 (60)
Patients on vasodilators	17 (68)
Patients on methotrexate	5 (20)
Patients on azathioprine	3 (12)
Patients on cyclophosphamide	1 (4)

SSc, systemic sclerosis; SD, standard deviation; mRSS, modified Rodnan Skin Score; MCP, metacarpo-phalangeal joint.

Supplementary Table 2. Association of miRNA21 with the clinical characteristics of systemic sclerosis patients.

miR-21			
		Median (n-n)	p
Smoking	Yes	3.32 (2.05, 4.6)	0.167
	No	6.30 (1.90, 17.50)	
Raynaud's phenomenon	Yes	6.17 (1.90, 17.50)	0.160
	No	2.05 (2.05, 2.05)	
Telangiectasia	Yes	6.04 (1.90, 17.50)	0.574
	No	5.55 (2.05, 12.90)	
Digital ulcers	Yes	10.20 (4.3, 16.80)	0.149
	No	4.75 (1.90, 17.50)	
Pitting scars	Yes	5.42 (2.70, 17.50)	0.598
	No	7.90 (1.90, 12.90)	
Arthralgia	Yes	5.55 (1.90, 17.50)	0.663
	No	6.04 (2.80, 10.20)	
Presence of ILD	Yes	6.17 (1.90, 17.50)	1
	No	4.80 (2.05, 16.80)	
Presence of PH	Yes	8.27 (4.3, 12.90)	0.73
	No	6.30 (1.90, 17.50)	
Dysphagia	Yes	7.90 (1.90, 17.50)	0.437
	No	4.75 (2.05, 13.06)	
Early SSc	Yes	7.75 (4.50, 16.80)	0.215
	No	6.04 (1.90, 17.50)	
SSc subtypes	Limited	5.42 (1.90, 17.50)	0.927
	Diffuse	10.50 (2.05, 12.40)	
	SSS	6.30 (2.70, 10.70)	
Significant PV by Medseger score	Yes	6.04 (2.7, 17.50)	0.475
	No	6.30 (1.90, 12.90)	
Significant skin by Medseger score	Yes	7.55 (2.05, 12.40)	0.780
	No	6.04 (1.90, 17.50)	
SSc patients on steroids	Yes	6.04 (1.90, 17.50)	0.81
	No	5.55 (2.70, 13.60)	
SSc patient on vasodilators	Yes	6.04 (2.80, 16.80)	0.55
	No	6.10 (1.90, 17.50)	

miR-21, miRNA21; n-n, range; ILD, interstitial lung disease; SSc, systemic sclerosis; SSS, systemic sclerosis sine scleroderma; PH, pulmonary hypertension; PV, peripheral vascular; *significant result.